Replies to post #193620 on Biotech Values

[DewDiligence]

LPTN—Due to the stock’s continuing to sell well below net cash per share, in due course LPTN will likely be the target of a reverse merger with a private company. In such a transaction, the private company will own the large majority of the merged company, and LPTN’s contribution will consist almost entirely of cash and the public listing.

[RNsidersbuying]

LPTN .27 - Twice now management has stated:

SAN DIEGO, May 20, 2015 - should be sufficient to fund the company's drug discovery and development activities through June 30, 2016.

SAN DIEGO, July 23, 2015 - should be sufficient to fund the company's drug discovery and development activities at least through June 30, 2016."

That's a total of 5 future q's since the 3/31/15 filed numbers - or with .56 HARD CASH remaining - we can deduce a burn average of .11 per quarter for the next five quarters?

SAN DIEGO, July 23, 2015 - Lpath will actively explore partnering, licensing and monetization options for its pipeline assets...Lpath's relationship with Pfizer, its partner on the iSONEP wet AMD program, remains cooperative...

Does anyone know another biotech trading at 1/2 cash with multiple pipeline assets and a 'cooperative relationship with Pfizer'??? I would hit your stock, Twice!